{"transactions":[{"id":3958644,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-04-23T16:16:47.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":7000000,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI\nand has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares\nheld by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee,\nwhich consists of S. Edward Torres, Dr. Steven E. Hall and Dr. Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims\nbeneficial ownership of the shares held by LVFI, except to the extent of his or its pecuniary interest therein. Dr. Shanafelt is a director of the\nIssuer and, accordingly, files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3181817},"source":{"system":"sec-edgar","filing":"0001209191-18-025824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025824/doc4.xml","form_type":"4"}},{"id":3958643,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T16:16:47.000Z","date":"2018-04-23","kind":"purchase","acquired":true,"shares":266000,"price":15,"value":3990000.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI\nand has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares\nheld by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee,\nwhich consists of S. Edward Torres, Dr. Steven E. Hall and Dr. Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims\nbeneficial ownership of the shares held by LVFI, except to the extent of his or its pecuniary interest therein. Dr. Shanafelt is a director of the\nIssuer and, accordingly, files separate Section 16 reports."}],"balance_after":3447817,"source":{"system":"sec-edgar","filing":"0001209191-18-025824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025824/doc4.xml","form_type":"4"}},{"id":3958642,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T16:16:47.000Z","date":"2018-04-23","kind":"exercise","acquired":true,"shares":3181817,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI\nand has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares\nheld by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee,\nwhich consists of S. Edward Torres, Dr. Steven E. Hall and Dr. Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims\nbeneficial ownership of the shares held by LVFI, except to the extent of his or its pecuniary interest therein. Dr. Shanafelt is a director of the\nIssuer and, accordingly, files separate Section 16 reports."}],"balance_after":3181817,"source":{"system":"sec-edgar","filing":"0001209191-18-025824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025824/doc4.xml","form_type":"4"}},{"id":4260828,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Series F Preferred Stock","published_at":"2017-07-07T23:16:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1443972,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its respective pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":145312},"source":{"system":"sec-edgar","filing":"0000899243-17-018092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1420565/000089924317018092/doc4.xml","form_type":"4"}},{"id":4260827,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Series E-3 Preferred Stock","published_at":"2017-07-07T23:16:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1654411,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its respective pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":166489},"source":{"system":"sec-edgar","filing":"0000899243-17-018092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1420565/000089924317018092/doc4.xml","form_type":"4"}},{"id":4260826,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Series E-2 Preferred Stock","published_at":"2017-07-07T23:16:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1907373,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its respective pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":191946},"source":{"system":"sec-edgar","filing":"0000899243-17-018092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1420565/000089924317018092/doc4.xml","form_type":"4"}},{"id":4260825,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Series D Preferred Stock","published_at":"2017-07-07T23:16:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":3390885,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its respective pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":341238},"source":{"system":"sec-edgar","filing":"0000899243-17-018092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1420565/000089924317018092/doc4.xml","form_type":"4"}},{"id":4260824,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common Stock","published_at":"2017-07-07T23:16:02.000Z","date":"2017-07-05","kind":"purchase","acquired":true,"shares":250000,"price":15,"value":3750000.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its respective pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports."}],"balance_after":1094987,"source":{"system":"sec-edgar","filing":"0000899243-17-018092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1420565/000089924317018092/doc4.xml","form_type":"4"}},{"id":4260823,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":167356,"kind":"organization","name":"LV Management Group, LLC","position":1,"cik":"0001681884","reported_name":"LV Management Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":138131,"kind":"person","name":"Hall Steven Edward","position":4,"cik":"0001602732","reported_name":"Hall Steven Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common Stock","published_at":"2017-07-07T23:16:02.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":844987,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its respective pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports."}],"balance_after":844987,"source":{"system":"sec-edgar","filing":"0000899243-17-018092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420565/000089924317018092/doc4.xml","form_type":"4"}},{"id":153844,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12398,"kind":"person","name":"Shanafelt Armen","position":3,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-04-14T23:35:05.000Z","date":"2016-04-12","kind":"exercise","acquired":true,"shares":2010924,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). LV Management Group LLC (the \"Management Company\") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This line item is being re-reported in order to gain access to the filing system. This Form is being amended to include Reporting Owners, Lilly Ventures Fund I LLC, and Dr. Shanafelt Armen as beneficial owners of the shares reported in the Form 4, previously filed by Eli Lilly and Company on April 14, 2016."}],"balance_after":2068543,"source":{"system":"sec-edgar","filing":"0000059478-16-000342","document":"wf-form4a_146067689367014.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947816000342/wf-form4a_146067689367014.xml","form_type":"4/A","original_submission_date":"2016-04-14"}},{"id":169048,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":false,"shares":543101,"ownership":{"direct":false,"nature":"By Group"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock and Series C Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":543101},"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169047,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":false,"shares":2333955,"ownership":{"direct":false,"nature":"By Group"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock and Series C Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2333955},"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169046,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"purchase","acquired":true,"shares":164963,"price":13.5,"value":2227000.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Lilly Ventures Fund I LLC purchased an additional 164,963 shares of Issuer's Common Stock in connection with the IPO at the offering price of $13.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":3042019,"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169045,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":true,"shares":543101,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":2877056,"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169044,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":true,"shares":2333955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":2333955,"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":174651,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"7% Convertible Promissory Notes","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"price":0,"reported_value":1084321.58,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"exercise_price":5.43,"underlying":"Common Stock","underlying_shares":199875},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174650,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"7% Convertible Promissory Notes","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"price":0,"reported_value":1345466.43,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":192209},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174649,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"shares":4340831,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":299213},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174648,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"shares":13513513,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":931485},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174647,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"purchase","acquired":true,"shares":733445,"price":7,"value":5134115.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":2356227,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174646,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":199875,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":1622782,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174645,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":192209,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":1422907,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174644,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":299213,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":1230698,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174643,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":931485,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":931485,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":178837,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":false,"price":0,"reported_value":5040221,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":0,"derivative":{"exercise_price":7.73,"underlying":"Common Stock","underlying_shares":672029},"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178836,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":false,"price":0,"reported_value":8640289,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":0,"derivative":{"exercise_price":5.25,"underlying":"Common Stock","underlying_shares":1152039},"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178835,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"purchase","acquired":true,"shares":142857,"price":14,"value":1999998.0,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":2081210,"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178834,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":true,"shares":672029,"price":7.73,"value":5194784.17,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":1938353,"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178833,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":true,"shares":1152039,"price":5.25,"value":6048204.75,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":1266324,"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}}]}